The patients who develop AIP may have lower dopamine availability in the synaptic cleft, which could facilitate the DRD2 blockade with antipsychotic drugs, and thus influence the risk of AIP development [24]. This evidence concerns the gene DRD2 and autoimmune pancreatitis.